Stocks bullish early but succumbs to sellers (ILU, WZR)
WHAT MATTERED TODAY
A poor day for the ASX with the market looking very strong for the first hour of trade only to succumb to sellers from around 11am onwards. The high was put in at 6113 keying off a reasonable lead from overseas markets however the selling in the higher value area of the market, tech and healthcare and the like prompted more broader based selling. The reflation trade we’ve harped on about for a while held up well, the Material stocks best on ground today up +0.87% while Credit Corp (CCP), a stock we covered in the AM note this morning (click here) finished up +8.76% on the day. Emeco (EHL), who reported yesterday and fell bucked the negative vibe today and rallied +7.58% to close at $1.065, recovering from yesterday’s weakness which we struggled to understand.
Overall, the ASX 200 fell -23pts / -0.39% to close at 6020. Dow Futures are trading up 1pts / +0.05%
ASX 200 Chart
ASX 200 Chart
CATCHING MY EYE
Iluka (ILU)+0.75% Released June Quarter production and sales numbers today that confirmed a challenging period for ILU – with global zircon headwinds noticeable in demand, sales offtake and pricing; the TiO2 feedstock side of the business (rutile) performed ok on price but volume was similarly lower. At the end of the quarter Iluka faced the stark realisation that offtake agreements are not necessarily “take or pay” – court ruling pending. A hard one to be bullish on given the confluence of trends across the business and more broadly.
Iluka (ILU) Chart
Wisr (WZR) -1.96%: alternative finance play Wisr was out with their 4th quarter update which showed more growth despite the resounding weakness in the broader economy. Loan originations for the quarter came in at $42.2m, 8% higher than the 3rdquarter, and nearly double that of the last quarter. Revenues followed suit, up 188% on pcp with the company now totalling $244.9m in originations. Further to this, 90 day+ arrears fell to a record low of 1.44% of the book, and the average credit score now an impressive 723. The growth did come at a cost, with operating cashflow at -$12.8m for the financial year. The trends are mostly improving for Wisr but the market wasn’t keen on giving it credit just yet. Shares finished lower despite touching recent highs intra-day. The company continues to show impressive results despite the COVID-19 impact on the economy.
Source; Wisr (WZR)
Liquidity remains strong with more than $44m in available funding. The fintech screens positively and should be further validated as the market share wins continue. We like the stock as a speculative play given the key driver, loan originations, continues to show solid growth.
Wisr (WZR) Chart
BROKER MOVES:
· Healius Cut to Neutral at Citi; PT A$3.35
· Nufarm Raised to Buy at UBS; PT A$5.19
· ResMed GDRs Raised to Neutral at Evans & Partners Pty Ltd
· Perpetual Raised to Add at Morgans Financial Limited
· Panoramic Resources Raised to Speculative Buy at Hartleys Ltd
· Adbri Raised to Outperform at Taylor Collison
OUR CALLS
No changes today
Major Movers Today
Have a great night
James, Harry & the Market Matters Team
Disclosure
Market Matters may hold stocks mentioned in this report. Subscribers can view a full list of holdings on the website by clicking here. Positions are updated each Friday, or after the session when positions are traded.
Disclaimer
All figures contained from sources believed to be accurate. All prices stated are based on the last close price at the time of writing unless otherwise noted. Market Matters does not make any representation of warranty as to the accuracy of the figures or prices and disclaims any liability resulting from any inaccuracy.
Reports and other documents published on this website and email (‘Reports’) are authored by Market Matters and the reports represent the views of Market Matters. The Market Matters Report is based on technical analysis of companies, commodities and the market in general. Technical analysis focuses on interpreting charts and other data to determine what the market sentiment about a particular financial product is, or will be. Unlike fundamental analysis, it does not involve a detailed review of the company’s financial position.
The Reports contain general, as opposed to personal, advice. That means they are prepared for multiple distributions without consideration of your investment objectives, financial situation and needs (‘Personal Circumstances’). Accordingly, any advice given is not a recommendation that a particular course of action is suitable for you and the advice is therefore not to be acted on as investment advice. You must assess whether or not any advice is appropriate for your Personal Circumstances before making any investment decisions. You can either make this assessment yourself, or if you require a personal recommendation, you can seek the assistance of a financial advisor. Market Matters or its author(s) accepts no responsibility for any losses or damages resulting from decisions made from or because of information within this publication. Investing and trading in financial products are always risky, so you should do your own research before buying or selling a financial product.
The Reports are published by Market Matters in good faith based on the facts known to it at the time of their preparation and do not purport to contain all relevant information with respect to the financial products to which they relate. Although the Reports are based on information obtained from sources believed to be reliable, Market Matters does not make any representation or warranty that they are accurate, complete or up to date and Market Matters accepts no obligation to correct or update the information or opinions in the Reports. Market Matters may publish content sourced from external content providers.
If you rely on a Report, you do so at your own risk. Past performance is not an indication of future performance. Any projections are estimates only and may not be realised in the future. Except to the extent that liability under any law cannot be excluded, Market Matters disclaims liability for all loss or damage arising as a result of any opinion, advice, recommendation, representation or information expressly or impliedly published in or in relation to this report notwithstanding any error or omission including negligence.
